Skip to main content

Table 3 Management of candidemia

From: Impact of host- and early treatment-related factors on mortality in ICU patients with candidemia: a bicentric retrospective observational study

VariablesTotal cohort (n = 68)30-day survivors (n = 31)30-day non-survivors (n = 37)P value
Initial antifungal agent*
 Micafungin41 (60.3)19 (61.3)22 (59.5)1.000
 Liposomal amphotericin B11 (16.2)6 (19.4)5 (13.5)0.531
 Fluconazole7 (10.3)2 (6.5)5 (13.5)0.442
 Voriconazole3 (4.4)2 (6.5)1 (2.7)0.588
 None during candidemia7 (10.3)2 (6.5)5 (13.5)0.442
Treatment ≤ 24 h following onset
 Appropriate antifungal therapy alone4 (5.9)3 (9.7)1 (2.7)0.324
 CVC removal alone19 (27.9)9 (29.0)10 (27.0)1.000
 Combined intervention5 (7.4)2 (6.5)3 (8.1)1.000
Treatment ≤ 48 h following onset
 Appropriate antifungal therapy alone9 (13.2)3 (9.7)6 (16.2)0.494
 CVC removal alone18 (26.5)8 (25.8)10 (27.0)1.000
 Combined intervention16 (23.5)9 (29.0)7 (18.9)0.396
  1. Values are given as n (%). CVC central venous catheter
  2. *Including antifungal agents used in inappropriate antifungal therapy